Aeterna Zentaris (AEZS) Tops Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Aeterna Zentaris Reports Second Quarter 2016 Financial and Operating Results
August 9, 2016 4:30 PM EDTNear-Term Major Inflection Point Approaching with Expected Completion of two Pivotal Phase 3 Programs in 2016
All $ amounts are in US Dollars
Key developments
Product development programs on track towards FDA submission in 2017 Zoptrex (zoptarelin doxorubicin) pivotal Phase 3 clinical program remains on track for completion in 2016 Macrilen (macimorelin) confirmatory Phase 3 Trial for the evaluation of AGHD also remains on track for completion in 2016 Zoptrex out-licensing activity successfully continues Zoptrex licensee in China and related territories, Sinopharm A-Think... More